アンギオスイートの世界市場：洞察、競合情勢、市場予測：2030年

世界のアンギオ（血管造影）スイートの市場規模は、2023年に21億8,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に5.75％のCAGRで拡大し、2030年には30億5,000万米ドルに達すると予測されています。アンギオスイート市場は、心臓疾患や循環器疾患の増加、世界の糖尿病患者数の増加、高齢者人口の増加などの要因によって収益が増加し、製品の安全性と精度をさらに高める最新技術の進歩によって、予測期間中（2024年～2030年）にアンギオスイート市場の収益が大きく伸びると予測されます。

アンギオスイート市場の注目すべき促進要因の1つは、冠動脈疾患、心臓発作、脳卒中などの心臓および心血管疾患の有病率の上昇です。例えば、米国疾病管理予防センター（Center for Disease Control and Prevention）によると（2023年）、米国では20歳以上の1,820万人が冠動脈疾患を患っています。Global Burden of Cardiovascular Diseases（2019）の調査によると、世界中の心臓および心血管疾患の有病率は、1990年の2億7,100万人から2019年には5億2,300万人へとほぼ倍増しています。同出典によると、虚血性心疾患と脳卒中は、すべての高所得国において、身体障害と死亡の主要な危険因子となっています。例えば、米国心臓協会（2019年）のデータによれば、2030年までに米国人口の41％以上が心血管疾患に罹患する可能性があります。この数字はさらに増加すると言われています。例えば、汎米保健機構（2023年）の報告によると、2019年には、障害調整生存年（DALY）が4,080万年、障害とともに生きた年（YLD）が450万年、失われた生命年（YLL）が3,640万年となっています。

当レポートでは、世界のアンギオスイート市場について調査し、市場の概要とともに、タイプ別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 アンギオスイート市場レポートのイントロダクション

第2章 アンギオスイート市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 アンギオスイート市場の主な要因分析

• アンギオスイート市場の促進要因
• アンギオスイート市場の抑制要因と課題
• アンギオスイート市場の機会

第5章 アンギオスイート市場におけるポーターのファイブフォース分析

第6章 アンギオスイート市場に対するCOVID-19の影響分析

第7章 アンギオスイートの市場概要

• タイプ別
• 用途別
• 地域別

第8章 アンギオスイート市場の世界企業シェア分析-主要3～5社

第9章 アンギオスイート市場の企業と製品プロファイル

• Siemens
• Koninklijke Philips N.V
• Lam Vascular and Associates
• Hitachi, Ltd.
• ESAOTE SPA
• IMRIS
• Onex Corporation
• Canon Inc.
• 3D Systems, Inc.
• General Electric
• Shimadzu Corporation
• GIMIAS
• FUJIFILM Holdings Corporation
• Hologic, Inc.
• Planmeca
• Mindray Medical International Limited
• ZEISS International
• Guerbet
• Surgical Science
• B. Braun

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Angio Suites Market
• Table 3: Angio Suites Market in Global (2021-2030)
• Table 4: Angio Suites Market in Global by Type (2021-2030)
• Table 5: Angio Suites Market in Global by Application (2021-2030)
• Table 6: Angio Suites Market in Global by Geography (2021-2030)
• Table 7: Angio Suites Market in North America (2021-2030)
• Table 8: Angio Suites Market in North America by Country (2021-2030)
• Table 9: Angio Suites Market in the US (2021-2030)
• Table 10: Angio Suites Market in Canada (2021-2030)
• Table 11: Angio Suites Market in Mexico (2021-2030)
• Table 12: Angio Suites Market in Europe (2021-2030)
• Table 13: Angio Suites Market in Europe by Country (2021-2030)
• Table 14: Angio Suites Market in France (2021-2030)
• Table 15: Angio Suites Market in Germany (2021-2030)
• Table 16: Angio Suites Market in the United Kingdom (2021-2030)
• Table 17: Angio Suites Market in Italy (2021-2030)
• Table 18: Angio Suites Market in Spain (2021-2030)
• Table 19: Angio Suites Market in Russia (2021-2030)
• Table 20: Angio Suites Market in Rest of Europe (2021-2030)
• Table 21: Angio Suites Market in APAC (2021-2030)
• Table 22: Angio Suites Market in APAC by Country (2021-2030)
• Table 23: Angio Suites Market in China (2021-2030)
• Table 24: Angio Suites Market in Japan (2021-2030)
• Table 25: Angio Suites Market in India (2021-2030)
• Table 26: Angio Suites Market in Australia (2021-2030)
• Table 27: Angio Suites Market in South Korea (2021-2030)
• Table 28: Angio Suites Market in Rest of APAC (2021-2030)
• Table 29: Angio Suites Market in Rest of World (2021-2030)
• Table 30: Angio Suites Market in RoW by Region (2021-2030)
• Table 31: Angio Suites Market in Middle East (2021-2030)
• Table 32: Angio Suites Market in Africa (2021-2030)
• Table 33: Angio Suites Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Angio Suites Market
• Figure 3: Angio Suites Market in Global (2021-2030)
• Figure 4: Angio Suites Market in Global by Type(2021-2030)
• Figure 5: Angio Suites Market in Global by Application(2021-2030)
• Figure 6: Angio Suites Market in Global by Geography(2021-2030)
• Figure 7: Angio Suites Market in North America (2021-2030)
• Figure 8: Angio Suites Market in North America by Country (2021-2030)
• Figure 9: Angio Suites Market in the US (2021-2030)
• Figure 10: Angio Suites Market in Canada (2021-2030)
• Figure 11: Angio Suites Market in Mexico (2021-2030)
• Figure 12: Angio Suites Market in Europe (2021-2030)
• Figure 13: Angio Suites Market in Europe by Country (2021-2030)
• Figure 14: Angio Suites Market in France (2021-2030)
• Figure 15: Angio Suites Market in Germany (2021-2030)
• Figure 16: Angio Suites Market in the United Kingdom (2021-2030)
• Figure 17: Angio Suites Market in Italy (2021-2030)
• Figure 18: Angio Suites Market in Spain (2021-2030)
• Figure 19: Angio Suites Market in Russia (2021-2030)
• Figure 20: Angio Suites Market in Rest of Europe (2021-2030)
• Figure 21: Angio Suites Market in APAC (2021-2030)
• Figure 22: Angio Suites Market in APAC by Country (2021-2030)
• Figure 23: Angio Suites Market in China (2021-2030)
• Figure 24: Angio Suites Market in Japan (2021-2030)
• Figure 25: Angio Suites Market in India (2021-2030)
• Figure 26: Angio Suites Market in Australia (2021-2030)
• Figure 27: Angio Suites Market in South Korea (2021-2030)
• Figure 28: Angio Suites Market in Rest of APAC (2021-2030)
• Figure 29: Angio Suites Market in Rest of World (2021-2030)
• Figure 30: Angio Suites Market in RoW by Region (2021-2030)
• Figure 31: Angio Suites Market in Middle East (2021-2030)
• Figure 32: Angio Suites Market in Africa (2021-2030)
• Figure 33: Angio Suites Market in South America (2021-2030)
• Figure 34: Angio Suites Market Drivers
• Figure 35: Angio Suites Market Barriers
• Figure 36: Angio Suites Market Opportunities
• Figure 37: PORTER'S Five Force Analysis

Angio Suites Market By Type (Single-Plane And Bi-Plane), By Application (Angiography, Angioplasty, Stenting, Bypass Surgery, Others), and by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to upsurge in the cases of heart and circulatory disorders, increase in the cases of diabetes, along with rising geriatric population and constant technological advancements in product design.

The Global Angio Suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030. The Angio Suites market is slated to witness increasing revenue owing to factors such as a rise in the cases of heart and circulatory disorders, a rise in the number of diabetic patients globally coupled with the rising geriatric population, along with latest technological advancements to further enhance product safety and precision is expected to result in appreciable revenue growth in the Angio Suites market during the forecast period (2024-2030).

Angio Suites Market Dynamics:

One of the noteworthy drivers of the Angio suites market is the rise in the prevalence of heart and cardiovascular disorders such as coronary artery disease, heart attacks, stroke, etc. For instance, according to the Center for Disease Control and Prevention (2023), 18.2 million people aged 20 years and above in the United States had Coronary Artery Disease, in the year 2023. According to a study by the Global Burden of Cardiovascular Diseases (2019), the prevalence of heart and cardiovascular diseases across the world have almost doubled from 271 million in 1990 to 523 million in the year 2019. According to the same source, Ischemic Heart Disease and stroke are the major risk factors for disability and deaths in all high-income countries. For example, as per the data from American Heart Association (2019), over 41% of the U.S. population is likely to suffer from cardiovascular diseases by 2030. These numbers are further said to increase. For example, according to the reports from Pan American Health Organization (2023), there were 40.8 million disability-adjusted life years (DALYs), 4.5 million years lived with disability (YLDs), and 36.4 million years of lost life (YLLs) in the year 2019.

With these staggering numbers of cardiovascular disorders, factors such as diabetes and old age are also responsible for contributing to heart risks. For instance, according to the International Diabetes Federation Report (2023), there were more than 535 million people inflicted with diabetes in the year 2023, and the number of affected people is estimated to reach 780-783 million by the year 2045. The aforementioned source also stated that the rising incidences of obesity and a sedentary lifestyle are likely to increase the chances of diseases like atherosclerosis.

Thus, the rising prevalence of heart diseases and diabetes along with the growing geriatric population is expected to drive the demand for angio suites, eventually leading the global angio suites market growth during the forecast period (2024-2030).

Another prominent factor responsible for the growth of the Angio Suites market is the constant technological developments taking place in the Angio suites market for product design, and for increasing its safety and precision. For instance, in October 2022, Yashoda Hospitals, located in Secunderabad, India launched a 'Bi-Plane Neuro Angio Procedure Suite' with DTAS (Direct to Angio Suite) technology used for providing quick and highly advanced treatment in cases of brain stroke and neurological emergencies such as heart attacks. In another instance, in May 2022, Philips announced FDA 510(k) clearance for its new MR 7700 3.0T MR system, giving high performance and precision for both research and advanced clinical diagnostics.

However, the lack of healthcare infrastructure in low-income countries and the dearth of skilled workforce in terms of surgeons and cardiologists in the medical industry may act as restraining factors for the Angio Suites market.

The Angio Suites market reported a setback for a short time owing to the implementation of lockdown as necessary measures to break the chain of the COVID-19 infection transmission. The COVID-19 pandemic resulted in the massive reorganization of healthcare services and carrying out medical procedures. Many countries segregated medical procedures based on the need for urgent medical care to streamline the workflow during the COVID-19 crisis and saw various medical procedures considered elective being suspended. For instance, according to an article published by the Health design Organization (2023), to avoid contamination, the patients were isolated and treated in separate angio suites equipped with ventilation systems. Procedures involving life-threatening conditions like thrombectomy for stroke, endovascular aortic aneurysm repair for aortic ruptures, non-deferrable oncologic treatments, and organ-saving procedures were performed in most hospitals in acute cases of emergency, during the pandemic. Thus, due to the use of angio suites and surgical procedures only in cases of utmost need, the angio suites market observed a stagnant phase during the Covid-19 pandemic. However, with the resumption of activities across industries including the healthcare sector, it has been uplifting the angio suites market with constant patient diagnosis and surgical treatments, during the forecast period from 2024-2030.

Angio Suites Market Segment Analysis:

Angio Suites Market by Type (Single-Plane and Bi-Plane), Application (Angiography, Angioplasty, Stenting, Bypass Surgery, Others), Geography (North-America, Europe, Asia-Pacific, Rest of the World).

Based on the Application segment of the Angio Suites market, the stenting category is projected to register significant growth in revenue in the Angio Suites market during the forecast period (2024-2030). This can be ascribed to an increase in stenting procedures around the world, required in acute cases of stroke. Owing to the rising prevalence of stroke cases globally, leading to serious consequences like disability and death, this segment of the Angio Suites Market is expected to generate considerable revenue during the forecast period. As per the reports from World Health Organization (2023), the prevalent cases of stroke were 15 million around the world, where 5 million of them were left disabled for a lifetime. In another example, according to the American Heart Association (2023), the prevalence of stroke in the United States in the year 2020 was 89.1 million, whereas that of ischemic stroke was 68.2 million and that of intracerebral hemorrhage was 18.9 million. The Global Stroke Fact Sheet (2023) of the World Stroke Organization (WSO) also reveals that the rates of people having a stroke has substantially risen, with a whopping 70% increase in the global stroke rate in 2019, as compared to 1990.

Further, considering the growing demand for this segment of the application, various new products are being launched in the market with technological advancements, for the diagnosis and treatment of strokes.

For instance, In June 2022, Siemens Healthineers, a part of Siemens, launched the Angiography System Artis Icono, for various applications like stenting, stroke diagnosis and treatment and others. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.

In September 2019, another example of one of the latest developments involving two big players in the angio suites industry is that of Onvision Needle Tip Tracking Technology, manufactured from the collaboration of Philips and B. Braun for the accurate diagnosis and treatment of stroke. In August 2020, this Onvision Needle Tip Tracking Technology received FDA clearance from the U.S Food and Drug Administration.

Therefore, as per the above-mentioned factors such as the increasing cases of stroke along with technological developments from key players, this segment of the Angio suites market is expected to grow significantly during the given forecast period (2024-2030).

North America is expected to dominate the overall Angio Suites Market:

Among all the regions, North America is expected to lead in revenue generation in the global Angio Suites market. This can be ascribed to the massive rise in the cases of heart disorders and diabetes, ultimately requiring diagnostic procedures and treatments like angiography, angioplasty, stenting, bypass surgery and others in the North American region. The most common types of heart diseases in North America, and specifically in the U.S are Coronary Artery disease and stroke. According to the Centre for Disease Prevention and Control (2023), in the year 2019, about 18.2 million people above the age of 20 had Coronary Artery Disease which was the biggest contributor to deaths in the U.S., responsible for 3,60,900 deaths in the same year.

Along with Coronary heart disease, the cases of stroke are also on the rise in the United States. For example, according to the Centre for Disease Control and Prevention (2023) of Stroke Statistics, every 40 seconds a person had a stroke in the United States. The same source also stated that on average 795,000 people have a stroke every year, with 610,000 stroke cases being the first.

Thus, owing to such a high prevalence of heart disorders and the presence of a large patient pool in the United States, many angio suites are getting FDA approvals for their commercial use in markets. For instance, in March 2022, Philips received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its angio suite Philips Capsule Surveillance solution, paving the way for widespread deployment across healthcare systems in the USA. The angio suite is capable of utilizing streaming data from virtually any connected medical device and helps in the analysis to generate actionable insights and alerts.

Along with the prevalence of heart disorders, diabetes has also been one of the major factors for the growth of the Angio Suites market in North America. According to the Centre for Disease Control and Prevention, National Diabetes Statistics (2023), more than 130 million people were living with diabetes or pre-diabetes in the year 2019. According to the same source, more than 1.4 million new cases of diabetes were diagnosed in people aged 18 years and above, in the year 2019.

Not only is the U.S. in North America, but Canada also one of the most affected countries by heart diseases like stroke. According to the American Health Association (2023), Canada stands the second most to be affected by stroke globally in the year 2023. Along with this, Canada also stands forward in the number of hospitalizations related to heart conditions.

For example, according to the Heart and Stroke Foundation of Canada (2023), 2.6 million hospitalizations happened in Canada in the year 2019, associated with some heart conditions such as vascular cognitive impairment or stroke. The source also mentioned that out of the total hospitalizations for heart disorders, 50% of hospitalizations were for structural heart disease, 35% for vascular cognitive impairment related conditions, and the rest 25% for heart failures. Owing to such a high prevalence of heart disorders and the rising number of hospitalizations requiring angio suites in the country, big companies are collaborating with small-scale industries to expand their range of treatment and expertise.

For instance, in June 2022, Canon Medical Systems decided to collaborate with The Harley Street Healthcare Group Canada to launch a group of innovative diagnostic centers across Ontario. The diagnostic center is said to possess a highly equipped Angiography suite with the latest X-ray generators, Molecular Imaging, Ultrasound, and Healthcare Informatics.

In another instance, in March 2019, Conavi Medical Inc. Canada received the Health Canada Medical Device License for its Novasight Hybrid System, which is an Angio Suite enabling simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) having the potential to improve clinical outcomes during angioplasty and stenting.

Therefore, the presence of a large patient population base with heart disorders, coupled with a rise in technological advancements and product launches for increasing the safety and precision of angio suites is expected to bolster the growth of the Angio suites market in the North American region during the forecast period.

Angio Suites Market Key Players:

Some of the key market players operating in the Angio Suites market include Siemens, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems Inc., General Electric, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B. Braun, and others.

Recent Developmental Activities in Angio Suites Market:

In June 2022, Siemens Healthineers, a part of Siemens, launched the Angiography System Artis Icono, for precise tumor embolization. It is enabled with new system mechanics and image chains for 2D and 3D imaging with seamless integration and a third-party interface.

In December 2022, GE Healthcare, an auxiliary company of well-known Massachusetts, United states-based company "General Electric" announced the successful acquisition of Boston, United States-based imaging company "BK Medical."

In December 2020, GE Healthcare launched the Allia IGS 7 angiography system which is a new version of its robotic-driven angiography system for image-guided therapy, at the Radiological Society of North America (RSNA) virtual meeting 2020.

Key Takeaways from the Angio Suites Market Report Study

• Market size analysis for current Angio Suites market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Angio Suites market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years.
• Key companies dominating the global Angio Suites market.
• Various opportunities available for the other competitor in the Angio Suites market space.
• What are the top performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Angio Suites market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Angio Suites market growth in the coming future?

Target Audience who can be benefited from this Angio Suites Market Report Study

• Angio Suite providers
• Research organizations and consulting companies
• Angio Suites -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Angio Suites and equipments
• Various end users who want to know more about the Angio Suites market and latest technological developments in the Angio Suites market.

Frequently Asked Questions for Angio Suites Market:

1. What are Angio Suites?

An angio suite is an examination room where complex surgical procedures like angiography, stenting, bypass surgery, etc. are performed with high precision. It helps in the detection and observation of damaged blood vessels present in different organs, helping in the diagnosis and treatment of conditions like aneurysms, vascular stenosis, coronary atherosclerosis, etc.

2. What is the market for Global Angio Suites?

The Global Angio Suites market was valued at USD 2.18 billion in 2023, growing at a CAGR of 5.75% during the forecast period from 2024 to 2030 to reach USD 3.05 billion by 2030

3. What are the drivers for the Global Angio Suites market?

The Angio Suites market is expected to grow significantly owing to factors such as a rise in the prevalence of heart and circulatory disorders requiring procedures such as angioplasty, angiography, stents, bypass, myelography, etc. along with the rising geriatric population globally. The rapidly growing diabetic population coupled with technological advancements in the Angio Suites market for delivering quality treatment with better precision is further expected to result in appreciable revenue growth in the Angio Suites market during the given forecast period (2024-2030).

4. Who are the key players operating in Global Angio Suites Market?

Some of the key market players operating in the Angio Suites market include Siemens, Koninklijke Philips N.V, Lam Vascular and Associates, Hitachi, Ltd., ESAOTE SPA, IMRIS, Onex Corporation, Canon Inc., 3D Systems Inc., General Electric, Shimadzu Corporation, GIMIAS, FUJIFILM Holdings Corporation, Hologic, Inc., Planmeca, Mindray Medical International Limited, ZEISS International, Guerbet, Surgical Science, B. Braun, and others.

5. Which region has the highest share in the Angio Suites market?

North America is expected to dominate the overall Angio Suites market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a large patient population with heart diseases and diabetes, which can also be ascribed to the reason for the rising geriatric population in the North American region. In addition, it is a highly potent market in terms of technological developments and launches along with the presence of key market players among other factors in the region.

Table of Contents

1.Angio Suites Market Report Introduction

2.Angio Suites Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Angio Suites Market Key Factors Analysis

• 4.1. Angio Suites Market Drivers
  • 4.1.1. Rise in the cases of heart and circulatory disorders
  • 4.1.2. An increasing population of diabetic patients
  • 4.1.3. Technological advancements in product design
• 4.2. Angio Suites Market Restraints and Challenges
  • 4.2.1. High costs of installation
  • 4.2.2. Lack of skilled workforce and medical infrastructure
• 4.3. Angio Suites Market Opportunities
  • 4.3.1. Improving Product safety and precision

5. Angio Suites Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Angio Suites Market

7. Angio Suites Market Layout

• 7.1. By Type:
  • 7.1.1. Single-plane
  • 7.1.2. Bi-plane
• 7.2. By Application:
  • 7.2.1. Angiography
  • 7.2.2. Angioplasty
  • 7.2.3. Stenting
  • 7.2.4. Bypass Surgery
  • 7.2.5. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Angio Suites Market in USD million (2021-2030)
    • 7.3.1.2. Canada Angio Suites Market in USD million (2021-2030)
    • 7.3.1.3. Mexico Angio Suites Market in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Angio Suites Market in USD million (2021-2030)
    • 7.3.2.2. Germany Angio Suites Market in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Angio Suites Market in USD million (2021-2030)
    • 7.3.2.4. Italy Angio Suites Market in USD million (2021-2030)
    • 7.3.2.5. Spain Angio Suites Market in USD million (2021-2030)
    • 7.3.2.6. Russia Angio Suites Market in USD million (2021-2030)
    • 7.3.2.7. Rest of Europe Angio Suites Market in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Angio Suites Market in USD million (2021-2030)
    • 7.3.3.2. Japan Angio Suites Market in USD million (2021-2030)
    • 7.3.3.3. India Angio Suites Market in USD million (2021-2030)
    • 7.3.3.4. Australia Angio Suites Market in USD million (2021-2030)
    • 7.3.3.5. South Korea Angio Suites Market in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia Pacific Angio Suites Market in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Angio Suites Market in USD million (2021-2030)
    • 7.3.4.2 Africa Angio Suites Market in USD million (2021-2030)
    • 7.3.4.3 South America Angio Suites Market in USD million (2021-2030)

8. Angio Suites Market Global Company Share Analysis - Key 3-5 Companies

9. Angio Suites Market Company and Product Profiles

• 9.1. Siemens
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Koninklijke Philips N.V
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Lam Vascular and Associates
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Hitachi, Ltd.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. ESAOTE SPA
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. IMRIS
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Onex Corporation
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Canon Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. 3D Systems, Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. General Electric
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Shimadzu Corporation
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. GIMIAS
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. FUJIFILM Holdings Corporation
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Hologic, Inc.
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Planmeca
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Mindray Medical International Limited
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. ZEISS International
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Guerbet
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Surgical Science
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. B. Braun
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us